R&D
![neuron or nerve cell](https://pharmaphorum.com/wp-content/uploads/2023/01/neuron-or-nerve-cell.jpg)
Novartis’ Kesimpta, ECTRIMS 2022, and relapsing multiple scl...
Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta (